Loading
In children with average-risk leukaemia, adding blinatumomab pushed three-year disease-free survival from 88% to 96%, one of the largest gains in decades.
1,440 randomised children with standard-risk average or high subsets. 3-year DFS 96.0% vs 87.9% (HR 0.39, 95% CI 0.24-0.64); randomisation stopped early for efficacy. NEJM 2024. Led to FDA approval of blinatumomab in the consolidation phase for CD19+ Ph-negative B-ALL in children (June 2024) and is being adopted as the new paediatric standard.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,440 randomised.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival at 3 yearsprimary | Blinatumomab + chemotherapy | 722 | 96% | 0.39 (0.24 to 0.64) | <0.001 | link |
| Chemotherapy | 718 | 87.9% |
Shares Blinatumomab added to frontline chemotherapy, Standard-risk B-cell acute lymphoblastic leukaemia in children, Blinatumomab, CD3.
Shares Blinatumomab, CD3, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, CD19.
Shares Blinatumomab added to frontline chemotherapy, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, CD3.
Shares Standard-risk B-cell acute lymphoblastic leukaemia in children, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Rare and paediatric cancers without markets.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets, T-cell engagers (bispecific).
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.